Clinical trials: Diabetes Mellitus Type 2 (T2DM)
Diabetes Mellitus, Non-Insulin-Dependent
Effect of Laparoscopic Roux-en-Y Gastric Bypass Surgery on Non-severe Obesity With Type 2 Diabetes Mellitus
The effect of roux-en-Y gastric bypass(RYGB) on patients with type 2 diabetes mellitus(T2DM) and a body mass index(BMI)>35kg/m2 is clear.
- Trial name
- NCT02091323
- Testing
- gastric bypass surgery
- Where
- China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Guangzhou General Hospital of Guangzhou Military Command
Type 2 Diabetes Mellitus (T2DM)
A Study to Observe How Insulin Glargine 300 U/ml is Working and is Tolerated in Elderly Patients ≥75 Years of Age With Type 2 Diabetes
Primary objective: Glycemic control after initiation or switch to insulin glargine 300 U/ml in everyday clinical practice Secondary objective: Treatment satisfaction
- Trial name
- ELDERLY-T (NCT05607160)
- Where
- Germany
- Volunteers
- 82 people
- Sponsor
- Sanofi
T2DM (Type 2 Diabetes Mellitus), Diet, Healthy
Substitution of Sulfonylureas With New Generation of Hypoglycemic Drugs for the Treatment of Type 2 Diabetes Mellitus
This is a multicentric, prospective, parallel groups study. Patient recruitment will be carried out at the U.O. Departmental Endocrinology and Diabetology ASST FBF Sacco, Fatebenefratelli and Ophthalmic Hospital, and at the SSD…
- Conditions
- T2DM (Type 2 Diabetes Mellitus), Diet, Healthy, Renal Function Disorder, Albuminuria
- Trial name
- Sulfa-Zero (NCT04272359)
- Testing
- Sulfa-zero: possible benefits of the treatment of new generation hypoglycaemic drugs compared to sulphonylureas
- Where
- Italy
- Volunteers
- 138 people, healthy volunteers welcome
- Sponsor
- University of Milan
Atrial Fibrillation, T2DM (Type 2 Diabetes Mellitus)
RE-ELECT. Dabigatran vs Warfarin in AF Patients With T2DM and CKD
Kidney function in patients with atrial fibrillation (AF) is tending to decline over a time which is clearly demonstrated in clinical studies.
- Conditions
- Atrial Fibrillation, T2DM (Type 2 Diabetes Mellitus), Chronic Kidney Diseases
- Trial name
- RE-ELECT (NCT03789695)
- Testing
- Dabigatran Etexilate
- Where
- Russia
- Volunteers
- 200 people
- Sponsor
- Irina Ermolaeva
Type 2 Diabetes
Glycaemic Control of Weekly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes
The purpose of this study is to determine the optimal dose or doses of HM11260C, when administered once a week under the skin, to improve the control of blood sugar levels in patients with early-stage type 2 diabetes mellitus…
- Trial name
- NCT02057172
- Testing
- HM11260C, liraglutide
- Where
- United States
- Volunteers
- 254 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Type 2 Diabetes
Study to Evaluate Safety and Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Aged 10-24 Years
A trial of patients aged 10-24 years with type 2 diabetes mellitus to evaluate the comparative efficacy and safety between dapagliflozin and Placebo.
- Trial name
- NCT02725593
- Testing
- Dapagliflozin
- Where
- 42 sites in United States, Hungary and 5 more
- Volunteers
- 72 people
- Sponsor
- AstraZeneca
T2DM (Type 2 Diabetes Mellitus)
A Study to Evaluate the Efficacy, Safety, and Tolerability of ASC30 Tablets in Participants With Type 2 Diabetes Mellitus
This randomized, double-blind, placebo-controlled Phase II study is designed to evaluate the efficacy, safety, and tolerability of ASC30 oral tablets formulation in participants with Type 2 Diabetes Mellitus
- Trial name
- NCT07321678
- Testing
- ASC30 tablets
- Where
- 8 sites in United States
- Volunteers
- 100 people
- Sponsor
- Ascletis Pharma (China) Co., Limited
Type 2 Diabetes Mellitus, T2DM
Study to Evaluate HM15275 in Subjects With Type 2 Diabetes Mellitus
This study is a Phase 2 clinical trial to evaluate the efficacy, safety, and tolerability of HM15275 in subjects with type 2 diabetes mellitus over 36 weeks.
- Trial name
- NCT07527650
- Testing
- HM15275
- Where
- 20 sites in United States
- Volunteers
- 180 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Type 2 Diabetes Mellitus
Effect of Gene Polymorphisms on GLP-1 Receptor Agonists Response in Patients With T2DM
1. This is an prospective study to evaluate the effect of gene polymorphisms on therapeutic responses to glucagon like peptide-1 receptor agonist (GLP-1 RA) in patients with T2DM. 2.
- Trial name
- NCT05037045
- Testing
- GLP-1 receptor agonist
- Where
- China
- Volunteers
- 338 people
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
Schizophrenia, Type 2 Diabetes Mellitus
Janssen - Glucose Regulation/Risp/Olanz
Abnormalities in peripheral glucose regulation and type 2 diabetes can occur more commonly in individuals with schizophrenia than in healthy subjects or in other psychiatric conditions.
- Trial name
- NCT00205738
- Testing
- Risperidone, Olanzapine
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Diabetes Mellitus, Obesity
Single Loop DJB Sleeve Gastrectomy for Poorly Controlled T2DM
Type 2 diabetes mellitus (T2DM) is a chronic progressive illness affecting a substantial percentage of the general population. While pharmacotherapy remains the mainstay of treatment, around 60% of patients cannot achieve the…
- Conditions
- Diabetes Mellitus, Obesity, Bariatric Surgery Candidate, Weight Loss
- Trial name
- NCT03125369
- Testing
- Sleeve gastrectomy + duodeno-jejunal bypass, Roux-Y gastric bypass
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Chinese University of Hong Kong
Obesity in Diabetes, Type 2 Diabetes Mellitus (T2DM)
A Study to Evaluate the Efficacy and Safety of Once-Weekly MET097 in Adults With Obesity or Overweight and T2DM
This study is designed to test how well once-weekly MET097 (an ultra-long-acting GLP-1 receptor agonist) works to treat adults with obesity or overweight and type 2 diabetes mellitus (T2DM) compared to placebo.
- Trial name
- VESPER-2 (NCT06897202)
- Testing
- MET097 Injection
- Where
- 29 sites in United States
- Volunteers
- 133 people
- Sponsor
- Pfizer
T2DM, Type 2 Diabetes Mellitus
A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Dulaglutide in Participants With T2DM
The aim of the study is to compare the efficacy and safety of two XW003 doses versus dulaglutide as add-on therapy to metformin in participants with type 2 diabetes mellitus (T2DM)
- Trial name
- NCT05680129
- Testing
- Ecnoglutide high dosage, Ecnoglutide low dosage, Dulaglutide
- Where
- China
- Volunteers
- 623 people
- Sponsor
- Hangzhou Sciwind Biosciences Co., Ltd.
Type 2 Diabetes Mellitus
Assessing the Efficacy, Safety, and Tolerability of Met DR in Subjects With T2DM Over 12 Weeks
This study compared the effect of delayed-release metformin (Met DR) to placebo and extended release metformin (Met XR) on glycemic control (fasting plasma glucose and HbA1c) and body weight, and assessed the safety and…
- Trial name
- NCT01819272
- Testing
- Met DR, Met XR
- Volunteers
- 240 people
- Sponsor
- Elcelyx Therapeutics, Inc.
Diabetes Mellitus, Type 2
Study Of GW823093 In Japanese Subjects With Type 2 Diabetes Mellitus
To investigate the preliminary pharmacokinetics, pharmacodynamics, safety and tolerability of GW823093 at doses of 15mg and 30mg given once daily for 7 days in Japanese Type 2 diabetes mellitus (T2DM) patients.
- Trial name
- NCT00372957
- Testing
- GW823093 15mg, GW823093 30mg
- Volunteers
- 30 people
- Sponsor
- GlaxoSmithKline
Type 2 Diabetes Mellitus
Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Insulin Glargine Alone on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in Japan
Primary Objective: To compare LixiLan to insulin glargine in glycated hemoglobin (HbA1c) change from baseline to Week 26 in patients with type 2 Diabetes.
- Trial name
- LIXILAN JP-O2 (NCT02752828)
- Testing
- Insulin glargine/lixisenatide (HOE901/AVE0010), Insulin glargine (HOE901), Oral anti-diabetic drugs
- Where
- 113 sites in Japan
- Volunteers
- 521 people
- Sponsor
- Sanofi
Diabetes
Evaluation of a Nutritional Product for People With Type 2 Diabetes
The objective of this trial is to evaluate a nutritional product for people with Diabetes.
- Trial name
- NCT01850810
- Testing
- Experimental Study Product, Control Study Product
- Where
- 2 sites in United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Abbott Nutrition
Obesity, Type 2 Diabetes Mellitus (T2DM)
Magnetic Duodeno-Ileal Chile Study
The objective of the MagDI Chile Study is to evaluate the feasibility / performance, safety, and initial efficacy of the MagDI System in eligible participants who are indicated for a duodeno-ileal (small bowel) side-to-side…
- Trial name
- NCT06613724
- Testing
- Magnet System, DI Biofragmentable
- Where
- Chile
- Volunteers
- 10 people
- Sponsor
- GT Metabolic Solutions, Inc.
Type 2 Diabetes Mellitus (T2DM), Non-Alcoholic Fatty Liver Disease (NAFLD)
A Phase 1b Study of QX1206 in T2DM Patients With NAFLD
This is an open label phase 1b trial of QX1206 in patients with T2DM and with NAFLD. Laboratory tests and other measurements will be assessed prior to the first dose of study treatment and throughout the study to determine the…
- Trial name
- NCT06694935
- Testing
- QX1206
- Where
- Canada
- Volunteers
- 52 people
- Sponsor
- 1Globe Health Institute
Type 2 Diabetes
To Study Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1656 in Japanese Type 2 Diabetes Mellitus (T2DM) Patients
The purpose of this study is to assess the safety and tolerability of AZD1656 after multiple repeated oral doses in Japanese patients with type 2 diabetes.
- Trial name
- JMAD (NCT00916604)
- Testing
- AZD1656
- Where
- 2 sites in Japan
- Volunteers
- 24 people
- Sponsor
- AstraZeneca